Unknown OBSERVATIONAL NCT05388890

Treatment of Atrophic Gastritis After HP Eradication With Modified Liujunzi Decoction Based on Syndrome Differentiation

Clinical Study on the Efficacy of Modified Liujunzi Prescription on the Treatment of Atrophic Gastritis After HP Eradication

Sponsor: Peking University First Hospital

Conditions Chronic Atrophic Gastritis

Interventions MLD WFC

Updated 6 times since 2022 Last updated: Sep 1, 2023 Started: Aug 2, 2022 Primary completion: Dec 31, 2024 Completion: Dec 31, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05388890, this observational or N/A phase trial focuses on Chronic Atrophic Gastritis and remains ongoing. Sponsored by Peking University First Hospital, it has been updated 6 times since 2022, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Feb 2026 — Present [monthly]

Unknown

Status: Recruiting → Unknown
Sep 2024 — Feb 2026 [monthly]

Recruiting
Jul 2024 — Sep 2024 [monthly]

Recruiting
Oct 2023 — Jul 2024 [monthly]

Recruiting
Nov 2022 — Oct 2023 [monthly]

Recruiting

▶ Show 1 earlier version

Jun 2022 — Nov 2022 [monthly]

Recruiting

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Peking University First Hospital

Data source: Peking University First Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China